Patient-derived AMOTL1 mutations lead to defective cell migration and tissue development

Jiaqian Luo1, Ruxin Jin1, Fang Geng2,3

  • 1Institute of Pediatrics, Children's Hospital of Fudan University, and Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.

Bioscience Reports
|April 21, 2026
PubMed
Summary

Mutations in Angiomotin-like 1 (AMOTL1) disrupt its interaction with Tankyrase, causing protein buildup and inhibiting cell migration, leading to congenital defects.

Related Concept Videos